We are live on ! Find out more
AMED

Amedisys

Delisted

AMED was delisted on the 14th of August, 2025.

285 hedge funds and large institutions have $3.51B invested in Amedisys in 2019 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 105 increasing their positions, 105 reducing their positions, and 75 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.44% more ownership

Funds ownership: 88.11%90.56% (+2.4%)

1% more capital invested

Capital invested by funds: $3.47B → $3.51B (+$44.8M)

0% more repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 105

10% less funds holding

Funds holding: 317285 (-32)

35% less first-time investments, than exits

New positions opened: 49 | Existing positions closed: 75

48% less call options, than puts

Call options by funds: $15.7M | Put options by funds: $30.5M

Holders
285
Holders Change
-32
Holders Change %
-10.09%
% of All Funds
6.19%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
49
Increased
105
Reduced
105
Closed
75
Calls
$15.7M
Puts
$30.5M
Net Calls
-$14.8M
Net Calls Change
+$1.33M
Name Holding Trade Value Shares
Change
Change in
Stake
Public Sector Pension Investment Board (PSP Investments)
301
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
-$1.68M -13,600 Closed
Balyasny Asset Management
302
Balyasny Asset Management
Illinois
-$1.51M -12,267 Closed
GFPC
303
Global Financial Private Capital
Florida
-$1.22M -9,854 Closed
CI
304
Cavalier Investments
Georgia
-$1.21M -9,800 Closed
Bessemer Group
305
Bessemer Group
New Jersey
-$1.11M -9,000 Closed
EMG
306
Ellington Management Group
Connecticut
-$1.08M -8,800 Closed
PP
307
Paloma Partners
Connecticut
-$1.04M -8,443 Closed
Mitsubishi UFJ Trust & Banking
308
Mitsubishi UFJ Trust & Banking
Japan
-$1.04M -8,418 Closed
SSA
309
Schonfeld Strategic Advisors
New York
-$1.02M -8,300 Closed
SCA
310
Secor Capital Advisors
New York
-$1M -8,155 Closed
ECM
311
Element Capital Management
New York
-$994K -8,062 Closed
WCM
312
Weld Capital Management
New York
-$905K -7,344 Closed
Massachusetts Financial Services
313
Massachusetts Financial Services
Massachusetts
-$825K -6,691 Closed
Verition Fund Management
314
Verition Fund Management
Connecticut
-$777K -6,303 Closed
GCM
315
Gunderson Capital Management
South Carolina
-$706K -5,728 Closed
BCM
316
Bayesian Capital Management
New York
-$703K -5,700 Closed
NAM
317
NorthCoast Asset Management
Connecticut
-$676K -5,485 Closed
Simplex Trading
318
Simplex Trading
Illinois
-$644K -5,423 Closed
IG
319
ING Group
Netherlands
-$550K -4,464 Closed
BDF
320
Balasa Dinverno & Foltz
-$544K -4,410 Closed
Asset Management One
321
Asset Management One
Japan
-$507K -4,112 Closed
Sumitomo Mitsui Trust Group
322
Sumitomo Mitsui Trust Group
Japan
-$503K -4,079 Closed
QC
323
Quadrature Capital
United Kingdom
-$498K -4,035 Closed
OAM
324
Origin Asset Management
United Kingdom
-$494K -4,006 Closed
AI
325
Atom Investors
Texas
-$409K -3,320 Closed

AMED Hedge Fund Activity: Q2 2019 in Review

285 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q2 2019, worth a combined $3.51B — up 1.3% from $3.47B a quarter earlier.

Sellers outnumbered buyers: 75 funds closed out of AMED and 49 opened new positions — a net loss of 26 holders — while 105 trimmed existing stakes and 105 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $119M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $88.9M sold.

  • 285 institutional investors held Amedisys (AMED) as of Q2 2019, down from 317 in Q1 2019.
  • Funds reported $3.51B of Amedisys stock for Q2 2019, up 1.3% quarter-over-quarter.
  • 49 funds opened new Amedisys positions in Q2 2019 and 75 closed out, a net change of -26 holders.
  • The largest Amedisys buyer in Q2 2019 was T. Rowe Price Associates, an estimated $119M added.
  • The largest Amedisys seller in Q2 2019 was Acadian Asset Management, an estimated $88.9M sold.

Based on aggregated 13F filings for Q2 2019.